Satralizumab
How it works: Medicines for NMOSD and MOGAD →
Enspryng
EU: Approved in the EU since 2021US: FDA approved 2020
- Molecule type
- Antibody
- Mechanism (ChEMBL)
- IL6Ralpha/GP130 antagonist
- Targets
- IL6Ralpha/GP130
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
1,687 reports in total, 1,307 marked serious.
- Neuromyelitis optica spectrum disorder295
- Off label use166
- Urinary tract infection137
- Pneumonia105
- No adverse event70
- Covid-1969
- Fatigue63
- Hypoaesthesia55
- Headache52
- Infection51
Trials
Key trials
Large trials with a reported result on their main goal.
- Satralizumab, phase 3
Completed · Phase 3 · NMOSD · Main goal met
- Satralizumab, phase 3
Completed · Phase 3 · NMOSD · Main goal met
Running now
- BEST-NMOSD
Recruiting · Phase 4 · NMOSD · ongoing
- SATURN
Recruiting · NMOSD · ongoing
- SAkuraSun
Recruiting · Phase 3 · NMOSD · ongoing
- Satralizumab
Recruiting · NMOSD · ongoing
- Meteoroid
Running, not recruiting · Phase 3 · MOGAD · ongoing
Other trials (2)
Completed small trials, dose-finding studies and trials in other diseases.
- Satralizumab, phase 4
Terminated · Phase 4 · NMOSD · stopped_other
- Azathioprine, phase 3
Completed · Phase 3 · NMOSD · results_posted_no_test
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error